Investors
VARL is financed by VacidKöksal Investment Group, the private investment vehicle of co-founders Taha Vacid and Haktan Köksal. The company maintains strict criteria for alignment with its scientific mission, operational independence, and long-term vision.
We do not seek capital for growth at any cost. We seek partners who understand that the value VARL creates is measured in decades, not quarters, and that the integrity of our science is not negotiable under any financial pressure.
VacidKöksal Investment Group
Majority ownership and primary capital provider. The investment group is structured to ensure that VARL's scientific mission remains insulated from short-term market pressures. All strategic decisions are made jointly by the co-founders with full board visibility.
What We Expect
External investors must demonstrate alignment with VARL's long-term thesis. We require minimum 5-year commitment horizons, no interference with scientific operations, and full acceptance of our governance structure. Capital that comes with conditions that compromise our mission is capital we do not need.
How We Create Value
VARL is a pharmaceutical company built on computational biology. Our platform exists to develop drugs, not to sell software. The API, the digital twins, the simulation engine: these are not products for the market. They are the tools we use to discover, validate, and bring treatments to patients faster and at a fraction of the cost that the current industry requires.
Our primary revenue source is pharmaceutical development. VARL's platform is designed to compress the drug discovery pipeline from 15 years to under 3, and reduce development costs from $2.6 billion to under $150 million per compound. We develop treatments internally, from computational discovery through preclinical validation, and bring them to market through strategic agreements with national health systems and international health organizations.
We do not believe in extractive pharmaceutical pricing. Our cost structure, built on computational validation rather than decades of physical experimentation, allows us to price treatments at levels that governments and health systems can afford. We negotiate directly with countries and public health institutions to ensure that every treatment we develop reaches every patient who needs it, not just those who can pay premium prices. Affordable access is not a charitable afterthought. It is built into the economics of our model from the beginning.
Our API is not a SaaS product open to anyone with a credit card. It is a controlled research infrastructure licensed exclusively to qualified institutions: research hospitals, pharmaceutical companies, agricultural organizations, and government agencies, under strict access agreements. API access enables partners to run their own simulations on our digital twin engine in parallel with our internal programs, accelerating discovery across the entire field. Licensing revenue from the API supports our R&D operations while expanding the reach of computational biology beyond what any single organization could achieve alone.
The same computational platform that discovers drugs also designs crop varieties, soil restoration protocols, and food safety systems. We develop agricultural solutions and license them to farming cooperatives, national agriculture ministries, and food system operators, again at pricing structured for broad access. Revenue from agricultural applications creates a diversified funding base that reduces our dependence on any single therapeutic program and ensures the platform continues to grow across domains.
The pharmaceutical industry generates over $1.4 trillion annually by charging the highest prices the market will bear. We believe there is a better model: develop treatments at a fundamentally lower cost, price them for universal access, and let volume and velocity replace margin and monopoly. When you can develop a drug in 3 years instead of 15 and validate it computationally instead of through a decade of physical trials, the economics change. Our investors are not betting on price power. They are betting on the compounding value of a platform that gets faster, smarter, and more capable with every treatment it develops.
Reports & Letters
Investor communications and strategic updates.
Investor Relations
For inquiries regarding investment opportunities or shareholder matters, contact our investor relations team directly.